Brief: Volitionrx Limited Announces Interim Results From 680-Subject Clinical Trial In Colorectal Cancer
26/02/2018 21:05
Feb 26 (Reuters) - Volitionrx Ltd VNRX.A :
* VOLITIONRX LIMITED ANNOUNCES INTERIM RESULTS FROM
680-SUBJECT
CLINICAL TRIAL IN COLORECTAL CANCER
* VOLITIONRX - STUDY DEMONSTRATES HIGH DETECTION RATES OF
STAGE I
CANCER,PRE-CANCEROUS ADENOMAS IN COLORECTAL CANCER SCREENING
TRIAL FOR NU.Q BLOOD TEST
* VOLITIONRX LTD - DATA IS EXPECTED FROM 680-SUBJECT
CLINICAL
TRIAL IN 2018
Source text for Eikon: ID:nPn3NPDMpa
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems